Secreted factors like IL-6 and TGF-β from CAFs reduce the expression of major histocompatibility complex (MHC) I and II molecules in melanoma cells, promoting resistance to CTL-based therapies [216, 217]. The gene discussed is TGFB1; the disease is melanoma.